Letter in response to “Our HER2 is same as yours”

Por Matsusaka, Satoshi, Yoshida, Kazuhiro
Publicado no Transl Gastroenterol Hepatol (2016)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab

Por Osumi, Hiroki, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Publicado no Onco Targets Ther (2015)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients

Por Sato, Yasuyoshi, Matsusaka, Satoshi, Suenaga, Mitsukuni, Shinozaki, Eiji, Mizunuma, Nobuyuki
Publicado no Onco Targets Ther (2015)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

Por Ohhara, Yoshihito, Suenaga, Mitsukuni, Matsusaka, Satoshi, Shinozaki, Eiji, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients

Por OSUMI, HIROKI, MATSUSAKA, SATOSHI, WAKATSUKI, TAKERU, SUENAGA, MITSUKUNI, SHINOZAKI, EIIJ, MIZUNUMA, NOBUYUKI
Publicado no Mol Clin Oncol (2015)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Yamaguchi, Toshiharu
Publicado no Drug Des Devel Ther (2015)

A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction

Por SUZUKI, SHUN-ICHI, MATSUSAKA, SATOSHI, HIRAI, MITSUHARU, SHIBATA, HARUMI, TAKAGI, KOICHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado no Int J Oncol (2015)

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Shinozaki, Eiji, Matsusaka, Satoshi, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

Por Suenaga, Mitsukuni, Mizunuma, Nobuyuki, Matsusaka, Satoshi, Shinozaki, Eiji, Ozaka, Masato, Ogura, Mariko, Chin, Keisho, Yamaguchi, Toshiharu
Publicado no Drug Des Devel Ther (2015)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report

Por Osumi, Hiroki, Matsusaka, Satoshi, Shinozaki, Eiji, Suenaga, Mitsukuni, Mingyon, Mun, Saiura, Akio, Ueno, Masashi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado em 2013

Secondary central nervous system lymphoma surrounding a region injured by subarachnoid hemorrhage and subsequent aneurysmal clipping

Por Murata, Yoriko, Hata, Yasuhiro, Noda, Yoshihiro, Matsusaka, Satoshi, Fukui, Naoki, Kadota, Tomohito, Iwata, Jun, Machida, Takuya, Yamagami, Takuji
Publicado no Biomed Rep (2017)

Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of...

Por OBA, MASARU, CHIN, KEISHO, KAWAZOE, YOSHIMASA, TAKAGI, KOICHI, OGURA, MARIKO, SHINOZAKI, EIJI, SUENAGA, MITSUKUNI, MATSUSAKA, SATOSHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado em 2011

Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

Por OBA, MASARU, CHIN, KEISHO, KAWAZOE, YOSHIMASA, TAKAGI, KOICHI, OGURA, MARIKO, SHINOZAKI, EIJI, SUENAGA, MITSUKUNI, MATSUSAKA, SATOSHI, MIZUNUMA, NOBUYUKI, HATAKE, KIYOHIKO
Publicado em 2011

Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

Por KUBOKI, YASUTOSHI, MIZUNUMA, NOBUYUKI, OZAKA, MASATO, OGURA, MARIKO, SUENAGA, MITSUKUNI, SHINOZAKI, EIJI, MATSUSAKA, SATOSHI, CHIN, KEISHOU, MATSUURA, MASAAKI, HATAKE, KIYOHIKO
Publicado em 2011

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chem...

Por Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Kumekawa, Yosuke, Ogura, Mariko, Ozaka, Masato, Matsusaka, Satoshi, Chin, Keisho, Yamamoto, Noriko, Mizunuma, Nobuyuki
Publicado no BMC Cancer (2015)

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy

Por Matsusaka, Satoshi, Kobunai, Takashi, Yamamoto, Noriko, Chin, Keisho, Ogura, Mariko, Tanaka, Gotaro, Matsuoka, Kazuaki, Ishikawa, Yuichi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Genes Cancer (2016)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)

Por Suenaga, Mitsukuni, Fujimoto, Yoshiya, Matsusaka, Satoshi, Shinozaki, Eiji, Akiyoshi, Takashi, Nagayama, Satoshi, Fukunaga, Yosuke, Oya, Masatoshi, Ueno, Masashi, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Publicado no Onco Targets Ther (2015)

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Por Suenaga, Mitsukuni, Mashima, Tetsuo, Kawata, Naomi, Wakatsuki, Takeru, Horiike, Yuki, Matsusaka, Satoshi, Dan, Shingo, Shinozaki, Eiji, Seimiya, Hiroyuki, Mizunuma, Nobuyuki, Yamaguchi, Kensei, Yamaguchi, Toshiharu
Publicado no Oncotarget (2016)

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer

Por Sebio, Ana, Matsusaka, Satoshi, Zhang, Wu, Yang, Dongyun, Ning, Yan, Stremitzer, Stefan, Stintzing, Sebastian, Sunakawa, Yu, Yamauchi, Shinichi, Fujimoto, Yoshiya, Ueno, Masashi, Lenz, Heinz-Josef
Publicado no Pharmacogenomics J (2015)

Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer

Por Suenaga, Mitsukuni, Cao, Shu, Zhang, Wu, Matsusaka, Satoshi, Okazaki, Satoshi, Berger, Martin D., Miyamoto, Yuji, Schirripa, Marta, Barzi, Afsaneh, Yamamoto, Noriko, Yamaguchi, Toshiharu, Lenz, Heinz-Josef
Publicado no Pharmacogenet Genomics (2021)